LENZ Therapeutics (LENZ) Net Cash Flow: 2022-2023
Historic Net Cash Flow for Therapeutics (LENZ) over the last 2 years, with Dec 2023 value amounting to -$7.7 million.
- Therapeutics' Net Cash Flow rose 11.00% to -$7.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$9.3 million, marking a year-over-year increase of 97.18%. This contributed to the annual value of -$14.9 million for FY2024, which is 59.85% down from last year.
- According to the latest figures from Q4 2023, Therapeutics' Net Cash Flow is -$7.7 million, which was up 75.58% from -$31.6 million recorded in Q3 2023.
- Therapeutics' Net Cash Flow's 5-year high stood at $70.4 million during Q1 2023, with a 5-year trough of -$191.9 million in Q1 2022.
- Over the past 2 years, Therapeutics' median Net Cash Flow value was -$25.2 million (recorded in 2022), while the average stood at -$42.3 million.
- Data for Therapeutics' Net Cash Flow shows a peak YoY increase of 136.67% (in 2023) and a maximum YoY decrease of 68.10% (in 2023) over the last 5 years.
- Therapeutics' Net Cash Flow (Quarterly) stood at -$8.7 million in 2022, then climbed by 11.00% to -$7.7 million in 2023.
- Its Net Cash Flow stands at -$7.7 million for Q4 2023, versus -$31.6 million for Q3 2023 and -$40.4 million for Q2 2023.